CBU
SLDB icon

CIBC Bancorp USA’s Solid Biosciences SLDB Stock Holding History

CIBC Bancorp USA’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$349K Buy
34,976
+1,407
+4% +$10.7K ﹤0.01% 1464
2026
Q1 		$242K Buy
+33,569
New +$216K ﹤0.01% 1519

Other funds holding SLDB

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

CIBC Bancorp USA's SLDB Position: Q2 2026 in Review

CIBC Bancorp USA increased its Solid Biosciences (SLDB) stake by 4.2% in Q2 2026, buying an estimated $10.7K and bringing the position to 34,976 shares worth $349K. The position accounts for ﹤0.01% of the portfolio, ranked #1464.

CIBC Bancorp USA first reported a position in SLDB in Q1 2026 and has held it in 2 quarters since. 145 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

  • CIBC Bancorp USA held 34,976 shares of Solid Biosciences worth $349K as of Q2 2026.
  • CIBC Bancorp USA bought 1,407 Solid Biosciences shares in Q2 2026, an estimated $10.7K.
  • Solid Biosciences made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q2 2026, its #1464 holding.
  • CIBC Bancorp USA first reported a position in Solid Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 145 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.